Adalimumab Mitigates Lumbar Radiculopathy in a Case of Ankylosing Spondylitis

Persaud, Trevor; Morgan, Richard; Thant, Hein Linn; DeAsis, Francis J.; Ferre, Felix; Diaz, José J.

doi:10.12659/ajcr.936600

Am J Case Rep

2022

DOI: 10.12659/ajcr.936600

|View full text |Cite

Adalimumab Mitigates Lumbar Radiculopathy in a Case of Ankylosing Spondylitis

Trevor Persaud

Richard Morgan

Hein Linn Thant

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

An Overview of Adalimumab Therapy for Ankylosing Spondylitis

Sukhanova,

Gilavian,

Melnik

et al. 2024

CRR

View full text Add to dashboard Cite

Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease known for causing pain, stiffness, and reduced mobility in the axial skeleton. Adalimumab, a tumor necrosis factor (TNF) inhibitor, has emerged as a promising therapeutic option for AS. Methods: This systematic review involved a comprehensive search of randomized controlled trials related to AS treatment, conducted in major databases such as MEDLINE, Google Scholar, and PubMed. The search terms encompassed ankylosing spondylitis, adalimumab, methotrexate, other non-biologic DMARDs, glucocorticoids, NSAIDs, and analgesics. A total of 14 randomized controlled trials with 4,500 participants were included in the review. Results: The review's results revealed that adalimumab demonstrated notable superiority when compared to a placebo. It effectively reduced disease activity, improved physical function, and lowered inflammatory markers such as C-reactive protein and erythrocyte sedimentation rate. Adalimumab demonstrated a favorable safety profile, with adverse events comparable to those observed with placebo. Conclusion: Based on the results, adalimumab is deemed an effective treatment for AS, showcasing its potential as a first-line therapeutic option. Notably, no significant increase in adverse events was observed compared to placebo. However, the conclusion emphasizes the need for further studies with extended follow-up durations to ascertain the long-term efficacy and safety of adalimumab in AS management. This systematic review provides valuable insights supporting the use of adalimumab in the treatment of AS and underscores the importance of ongoing investigations into its long-term effects to optimize its clinical utilization in AS patients.

show abstract

An Overview of Adalimumab Therapy for Ankylosing Spondylitis

Sukhanova,

Gilavian,

Melnik

et al. 2024

CRR

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Adalimumab Mitigates Lumbar Radiculopathy in a Case of Ankylosing Spondylitis

Cited by 1 publication

References 33 publications

An Overview of Adalimumab Therapy for Ankylosing Spondylitis

An Overview of Adalimumab Therapy for Ankylosing Spondylitis

Contact Info

Product

Resources

About